Figure 6. Model for prion protein–mediated resistance to anthracyclines.
Schematic illustration of the potential implications of high concentrations of PrPC, which could sequester anthracyclines in the tumor microenvironment, systemic circulation and/or distant tissues, reducing local bioavailability, and/or modifying pharmacokinetics and pharmacodynamics. Our data suggest that the effect is more pronounced for doxorubicin than epirubicin due to structural determinants of complex copper ion formation.